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Summary 
Background: Polyunsaturated fatty acids (PUFAs) play a
role in the development/progression of colon cancer. The
aim of the study was to assess the relation between serum
phospholipids PUFAs, colorectal tumour localization and
disease progression.   
Methods: A total of 67 patients (18 with proximal colon,
17 with distal colon and 32 with rectal tumour localization)
as well as 16 controls were studied. One year after surgery,
33 patients had disease progression. Serum levels of
C16:1(n-7), C18:1(n-9), C18:3(n-3), C20:5(n-3), C22:6(n-
3), C18:2(n-6), C20:2(n-6), C20:4(n-6) fatty acids of se -
rum phospholipids were quantitatively measured before
surgery by gas-chromatography. 
Results: Significantly higher mean value of C18:2, as com-
pared to control, has been noted only for patients with pro-
ximal (p<0.05) and distal tumour (p<0.03) localization.
The lower mean level of C20:5 and unsaturation index (UI)
were observed in colorectal cancer patients regardless the
tumour localization, but the statistical difference was noted
only for patients with proximal tumours (p<0.05, p<0.03).
In patients with proximal tumours, significantly lower mean
level of C20:4 and UI were noted in patients with disease
progression, as compared to patients with proximal tumo-
urs without disease progression (p<0.05). 
Kratak sadr`aj
Uvod: Polinezasi}ene masne kiseline (PUFA) imaju zna~ajnu
ulogu u razvoju/progresiji karcinoma kolona. Cilj ovog pro -
u~avanja je da ispita odnos izme|u PUFA serumskih fosfoli -
pida, lokalizacije kolorektalnog tumora i progresije oboljenja.
Metode: Prou~avano je ukupno 67 pacijenata (18 sa rektal-
nim tumorom lokalizovanim na proksimalnom kolonu, 17 na
distalnom kolonu i 32 u rektalnom delu), kao i 16 kontrolnih
osoba. Nivoi serumskih masnih kiselina C16:1(n-7),
C18:1(n-9), C18:3(n-3), C20:5(n-3), C22:6(n-3), C18:2 (n-
6), C20:2(n-6), C20:4(n-6) u fosfolipidima mereni su kvan-
titativno pre hirur{ke intervencije gasnom hromatografijom.
Rezultati: Na|ene su zna~ajno vi{e srednje vrednosti C18-2
u odnosu na kontrolnu grupu samo kod pacijenata sa proksi-
malnim (p<0,05) i distalnim (p<0,03) tumorom. Ni`e sred-
nje vrednosti C20:5 i nesaturacioni indeks (UI) na|eni su
kod pacijenata sa kolorektalnim tumorom, mada je sta -
tisti~ka razlika zabele`ena samo za pacijente sa proksimalnim
tumorom (p<0,05, p<0,03). U pacijenata sa proksimalnim
tumorom zna~ajno ni`e srednje vrednosti C20:4 i UI su
na|ene kod pacijenata sa progresijom oboljenja u pore|enju
sa pacijentima sa proksimalnim tumorom bez progresije
(p<0,05).
Zaklju~ak: Procena PUFA kao rizik/prognosti~kog faktora u
pacijenata sa kolorektalnim tumorom mo`e da se koristi za
procenu lokalizacije tumora kao zavisno promenljiva vred-
nost.
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Introduction
Colorectal cancer is not only a very heterogenous
disease but also various subsites of tumour location
can be seen. It has been proposed that colorectal can-
cer should be categorized into proximal and distal to
the splenic flexure localization (1). It was suggested
that the risk of colon cancer from environmental and
genetic factors is different for tumours located in pro-
ximal and distal locations (1). Recently, Li and Lai (2)
presented the evidence that colorectal cancer should
be divided into proximal colon cancer, distal colon
cancer, and rectal cancer because differences in phy-
siology and anatomy, environmental carcinogens,
genetic mechanisms, and prognosis between these
three cancer locations have been shown. According to
Sasazuki et al. (3), marine n-3 polyunsaturated fatty
acids (PUFAs) and specific PUFAs are inversely related
to the risk of colon cancer in the proximal site and no
such association for n-6 PUFAs has been observed.
Hodge et al. (4) observed a positive association with
dietary palmitic acid, MUFAs and n-6 PUFAs for rectal
but not for colon cancers. These could explain very
conflicting data regarding the relation between n-fatty
acids and colorectal cancer risk or progression.
Literature evidence suggests that the diet plays
an important role in colorectal cancer etiology and
development. There is a strong association between
dietary intake of saturated fat and colon cancer risk
(5). On the other hand, it has been shown that n-3
fatty acids may be responsible for reduced cancer risk
(6) or have no influence on cancer risk (7). Gerber
(8), based on a systematic update review of epide-
miological studies, summarized that limited evidence
and experimental data suggest a possible relationship
between n-3 PUFAs and colorectal cancer. However,
results of different studies regarding the role of fatty
acids (FAs) in colorectal cancer are conflicting, and
no convincing data exist linking FAs with the risk of
the disease (9). Also, the link between FAs serum
levels and localization of the tumour is not well
known. 
Numerous papers have already been published
on the importance of fatty acids in colorectal cancer
risk and prevention. However, little data exists on the
fatty acids of phospholipids fraction in patients with
colorectal cancer in relation to disease stage and
tumour location. Fatty acids of the phospholipids frac-
tion reflect the amount of fatty acids consumed with
a diet. It is known that the amount of monounsatura-
ted fatty acids (MUFAs) and polyunsaturated fatty
acids (PUFAs) correlates with the proportion of fatty
acids content in the serum phospholipids fraction
(10), thus individual fatty acids are not only good
markers of early dietary habits (11, 12) but may be
markers of cancer progression. The aim of the study
was to evaluate the link between the fatty acids of
phospholipids fraction, tumour localization and can-
cer progression in colorectal cancer patients.
Materials and Methods
Sixty-seven consecutive patients with colorectal
cancer (37 men and 30 women, mean age
63.4±10.2 years) were selected from patients atten-
ding the tertiary care University Hospital in Krakow,
Poland. The clinical diagnosis was based on physical
examination, colonoscopy, endorectal USG, abdomi-
nal CT, and histopathology of tissue specimens accor-
ding to Astler-Coller classification. Each patient
under went open surgery in order to remove the
tumour. The patients with diabetes mellitus or glucose
intolerance assessed based on fasting plasma glucose
level and oral glucose tolerance test (OGTT) were
excluded from the study. The study was approved by
the local Ethical Committee (KBET/14/B/2006, re -
sumed and expanded in 2013). 
According to the UICC/AJCC classification, two
patients (3%) were in stage 0 of the disease, 
24 patients (35.8%) in stage I, four patients (6%) in
stage II, 12 patients (17.9%) in stage III and 25
patients (37.3%) in stage IV. In 18 patients (26.9%)
the tumour was localized in the proximal colon, in 17
patients (25.4%) in the distal colon and in 32 (47.8%)
patients the tumour localization was confined to the
rectum. After one year of follow-up, 34 (50.7%)
patients were in stable condition and the remaining
33 (49.3%) patients had disease progression. All
patients were on free range diet. Sixteen healthy
patients (four men, 12 women, mean age 48.0±12
years) served as a control group. Both colorectal can-
cer patients and healthy subjects were on free diet. 
Fasting blood samples were taken from each
patient before surgery. Serum samples were stored at
–70 °C until biochemical measurement of serum fatty
acids of the phospholipids fraction was performed.
The analytical procedure consisted of a few separate
steps: 1) extraction of serum total lipids by Folch et al.
(13) method; 2) separation of lipid fraction on Sep-
PakNH2 columns (Waters, Milford, Mass., USA) (14);
3) methylation (15, 16) and separation of the fatty
acid from phospholipids fraction by gas-chromato -
Conclusions: The evaluation of PUFAs as a risk/prognostic
factor in colorectal cancer patients should take into account
tumour localization as a dependent variable. 
Keywords: polyunsaturated fatty acids, n-3 fatty acids,
n-6 fatty acids, phospholipids, colorectal cancer
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kiseline, n-6 masne kiseline, fosfolipidi, kolorektalni karci-
nom
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graphy (Agilent Technologies 6890N Network GC
Systems, Wilmington, De., USA) equipped with Agi -
lent J&W HP-88 capillary column (100 m, 0.250 mm,
0.20 mm) (Agilent Technologies, USA). As an internal
standard, 1,2-di pen ta decanoil-sn-glicero-3-phospho -
choline (Sigma-Aldrich, Steinheim, Germany) was
used. The method was calibrated using the calibra-
tion mixture (all fatty acids – Sigma-Aldrich, Stein heim,
Germany) and method validation was performed by
GC-MS (17). Plasma levels of n-7 (palmito leic, C16:1),
n-9 (oleic, C18:1), n-3 (alpha-linolenic, C18:3; eico-
sapentaenoic – EPA, C20:5; docosahexaenoic –
DHA, C22:6) and n-6 (linoleic, C18:2; eicosadienoic
C20:2; arachidonic, C20:4) acids of phospholipids
fraction were quantitatively measured by gas-chroma-
tography. The concentrations of fatty acids from
phos pholipids fraction were expressed in mmol/L. The
sum of monounsaturated fatty acids (MUFAs), poly-
unsaturated fatty acids of n-3 series (PUFAs n-3) and
n-6 (PUFAs n-6) series and unsaturation index (UI)
were calculated using the following formulas: 
MUFAs = C16:1 + C18:1;
PUFAs n-3 = C18:3 + C20:5 + C22:6; 
PUFAs n-6 = C18:2 + C20:2 + C20:4; 
UI = C16:1 + C18:1cis + C18:2cisx2 + C18:3x3
+ C20:2x2 + C20:4x4 + C20:5x5 + C22:6x6. 
Also, the ratio of n-6 to n-3 fatty acids was cal-
culated.
Statistical analysis was performed with the
software of Statistica 8.0 (StatSoft Inc., Krakow, Po -
land). The data are presented in the form of typical
descriptive statistics (mean, SE). The Shapiro-Wilk’s
test was used to determine the normality of data
distribution. Between groups comparison was per -
formed using one-way ANOVA test with Tukey’s
(unequal N) post hoc test. The level of statistical
significance was established at p<0.05.
Results
High inter-individual variability for all mono- and
polyunsaturated fatty acids measured, both in
Fatty acid 
[mmol/L]
Colorectal cancer patients
Tumour localization
Control
n=16
All
n=67
proximal
n=18
distal
n=17
rectum
n=32
Palmitoleic acid  C16:1 (n-7) 14.4±2.2 19.35±0.96p<0.05* 18.0±2.4 18.7±2.5 20.4±1.8
Oleic acid  C18:1 (n-9) 276.8±21.9 301.1±10.1 282.1±19.9 304.0±19.9 309.6±14.5 
Linoleic acid (LA) C18:2 (n-6) 503.8±42.7 643.4±19.7p<0.03* 
661.8±38.7
p<0.05* 
679.2±38.7
p<0.03* 614.6±28.2 
a-linolenic acid (ALA) C18:3 (n-3) 9.6±1.1 5.9±0.5p<0.03* 6.1±1.0 6.03±1.0 5.8±0.7 
Eicosadienoic acid C20:2 (n-6) 18.5±1.5 9.5±0.5p<0.001*
9.4±1.0
p<0.001*
10.0±1.1
p<0.001* 
9.3±0.8
p<0.001*
Arachidonic acid (AA) C20:4 (n-6) 523.7±30.7 386.0±13.9p<0.003*
378.5±27.1
p<0.007*
389.8±27.9
p<0.02*
388.2±18.3
p<0.02*
Eicosapentaenoic acid (EPA) C20:5 (n-3) 48.7±4.2 37.5±2.5p<0.05*
31.2±3.7 
p<0.05* 36.9±4.9 41.4±3.6
Docosahexaenoic acid (DHA) C22:6 (n-3) 260.7±17.3 164.0±7.8p<0.001*
160.1±15.3
p<0.001*
171.1±15.7
p<0.003*
162.4±8.5
p<0.001*
Indices
MUFAs 295.4±23.5 320.4±10.8 299.9±21.3 322.8±21.3 330.0±15.5 
PUFAs n-3 319.0±20.8 205.3±9.8p<0.001*
200.3±19.4
p<0.001*
208.4±19.4
p<0.003*
206.3±14.4
p<0.002*
PUFAs n-6 1046.0±60.8 1053.8±28.8 1074.5±56.9 1099.0±58.7 1021.1±40.9
UI *103 5.27±0.27 4.32±0.12p<0.02*
4.19±0.24
p<0.03* 4.48±0.24 4.32±0.18
PUFAs n-6/PUFAs n-3 3.8±0.39 5.34±0.2p<0.007*
5.39±0.37
p<0.03* 5.56±0.39
5.20±0.28
p<0.02*
Table I Mono- and polyunsaturated serum fatty acids (mmol/L) of phospholipids fraction in colorectal cancer patients in relation
to tumour localization.
Mean values ±SE are given. * as compared to control 
MUFAs – monounsaturated fatty acids,  PUFAs n-3 – polyunsaturated fatty acids of n-3 series, PUFAs n-6 – polyunsaturated fatty
acids of n-6 series
UI – unsaturation index 
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patients and in controls, has been noted. However,
there were no significant differences in the mean
values of all measured fatty acids of phospholipids
fraction and calculated indices between men and
women and among patients with different stage of
the disease. Taking into account all colorectal cancer
patients, the mean serum concentrations of C16:1
(n-7) and C18:2 (n-6) were significantly higher and
the mean levels of C18:3 (n-3), C20:2 (n-6), C20:4
(n-6), C20:5 (n-3) and C22:6 (n-3) were significantly
lower as compared to control (p<0.05–0.001). Only
the mean values of C18:1 (n-9) obtained in colorectal
cancer patients and in control were similar (Table I).
Among the calculated indices, the mean values of
MUFAs and PUFAs (n-6) did not differ between colo-
rectal cancer patients and control. However, signifi-
cantly lower mean values of PUFAs (n-3) (p<0.001)
and UI (p<0.02) were noted for colorectal cancer
patients as compared to control. The mean value of
PUFAs (n-6) to PUFAs (n-3) ratio was significantly
higher in colorectal cancer patients as compared to
control (p<0.007).
Taking into account tumour localization, similar
mean values of the measured fatty acids were found
except for linoleic acid (C18:2, n-6), EPA (C20:5, n-
3) and UI. Significantly higher mean values of linoleic
acid (C18:2, n-6), as compared to control, have been
noted for patients with proximal and distal tumour
localization but not for patients with tumours confined
to the rectum. Although the mean values of EPA and
UI were lower than in control regardless the tumour
localization, statistical difference was noted only for
patients with proximal tumour localization (for EPA
p<0.05, for UI p<0.03). Moreover, a significant trend
toward increased values of EPA from the proximal part,
to the distal part, to the rectum was noted (p<0.05)
(Figure 1).
In patients with proximal tumour localization
who have had disease progression after one year of
follow-up, a significantly lower mean value of C20:4
(n-6) has been observed as compared to the patients
having the same tumour localization but disease free
after one year  (respectively: 329.4±28.1; 439.9±
26.6; p<0.05). Patients with proximal tumour locali-
zation and disease progression had significantly lower
mean values of UI as compared to those with out
tumour progression (respectively: 3.73±0.22; 4.62±
0.21; p<0.05). No other differences between the
mean values of fatty acids measured in respect to
disease progression were observed.
Discussion
Fatty acids are very important biological com -
pounds which may be associated with different dis -
eases (e.g. diabetes) or are linked with an increased
risk of certain cancer. Literature evidence suggests
that dietary lipids could play an important role in the
etiology of colorectal cancer, although inconsistent
results are frequently seen (18). The role of different
lipids fraction has been already studied in cancer
patients, but measurement of plasma phospholipids
fatty acids can be considered as the most useful
because a correlation exists between dietary fatty acid
intake and the proportion of fatty acids in plasma
phospholipids (19, 20). It is known that PUFAs con-
tent in phospholipids fraction is mainly of exogenous
origin (11). Thus, it can be assumed that fatty acids
of phospholipids fraction reflect, to some extent, the
intake of fatty acids. Phospholipids are the predomi-
nant lipids of cell mem branes. 
The main goal of the present study was to find
out the relationship between the fatty acids composi-
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Figure 1 The mean concentration value of eicosapentaenoic acid (EPA) of serum phospholipid fraction in colorectal cancer
patients in relation to tumour location.
Unauthentifiziert   | Heruntergeladen  17.01.20 15:04   UTC
J Med Biochem 2018; 37 (1) 43
tion in serum phospholipids fraction and tumour loca-
lization in colorectal cancer patients. Most significant
finding in the present study is that the mean EPA
(C20:5, n-3) level and UI in patients with colorectal
cancer had the lowest value in patients with tumours
localized in the proximal part of the colon. The results
are in agreement with the data of Fernandez-Bañares
et al. (21) and Okuno et al. (22) who observed a signi-
ficantly lower percentage of EPA in plasma phospholi-
pids in colorectal cancer patients versus reference
group. However, the cited authors (22) did not find
significant differences in the proportion of any fatty
acid between patients with cancer located in the pro-
ximal colon, distal colon and rectum. Fernandez-
Bañares et al. (21) noticed a significantly lower UI in
cancer patients versus the control group. Their study
group consisted of patients with tumours in the rec-
tum, sigmoid colon and caecum plus ascending colon
and they did not compare the UI between patient sub-
groups. In our study, a decrease in UI in all patients
with colorectal cancer was observed; however, looking
at the different tumour locations, such a decrease was
noted only in patients with a proximal location of the
cancer. This confirms that histology of the cell mem-
brane in different parts of the intestine is variable.
Differen ces in UI between colorectal cancer patients
and controls indicate indirectly that any research con-
nected with membrane fluidity should always take into
consideration tumour localization. Sasazuki et al. (3),
based on a questionnaire, in a large Japanese popula-
tion-based study found that high fish consumption and
a wide range of n-3 PUFAs of marine origin are in -
versely related to the risk of cancer in proximal sites of
the large bowel. Significantly lower 5-year survival for
patients with proximal colon cancer compared to distal
colon cancer has also been published (23). Kantor et
al. (24) noticed the association between fish oil sup-
plement use and cancer risk to vary over anatomical
subsite. The enhancement of fish oil use reduced risk
of colon cancer, but not risk of rectal cancer.
The results of Okuno’s study demonstrated no
significant differences for C18:2 and C20:4 between
patients with colorectal cancer and controls (22).
Fernandez-Bañares et al. (21) and Baro et al. (25)
showed a significantly lower percentage of linoleic
acid in colorectal cancer patients than in a control
group, while the percentage of arachidonic acid was
similar to controls. In contrast, in our study the level
of C18:2 was higher whereas C20:4 level was lower
in colorectal cancer patients regardless of the tumour
localization. The mean concentrations of DHA and
PUFAs n-3 were lower in patients with cancer located
in the proximal part, distal part of the colon and in the
rectum as compared to the control group. However,
in three other studies there were no significant diffe-
rences for DHA between colorectal cancer patients
and control group when fatty acid was expressed as a
proportion of total FAs (22, 26, 27). Hodge et al. (4)
noticed an inverse association between plasma phos -
pholipids docosahexaenoic acid and risk of rectal can-
cer. The differences in fatty acids of phospholipids
fraction between colon cancer patients observed in
different studies can be due, in part, to modification
in the metabolism of fatty acids in cancer patients,
and in part to differences in dietary habits, race, and
geographical areas. Our cancer patients and controls
came from the same geographical area with a very
homogenous population, and an assumption can be
made that the diet in every subject was similar quan-
titatively.
Another important finding of our study is the
significantly (p<0.05) lower level of arachidonic acid
(AA) in patients with disease progression after one
year of observation as compared to the patients who
were disease-free; however, this observation was only
true for patients with proximal, but not distal or rectal
tumour location. The AA, associated with membrane
phospholipids, originates from linoleic acid (LA) pre-
sent in the diet (28). The rate-limiting step in the pro-
duction of AA from LA has been identified as micro-
somal D6 desaturation, and it has been elucidated
that the inhibition of this desaturation encumbers
tumorigenesis in a mouse model (29). AA is conver-
ted into eicosanoids with the help of cyclooxygenase
(COX) and lipoxygenase. It is known that colonic epi-
thelial cells transport dietary LA and convert LA to AA
more rapidly during transformation/tumorigenesis
(30). AA-derived eicosanoids have proinflammatory
effects (31–33). EPA-derived eicosanoids have anti-
inflammatory effects (34). The fatty acid profile ob -
tained in the present study differs from the results ob -
tained in patients with familial adenomatous polyposis
(35) in whom lower LA and higher AA as compared
to control have been obtained. Metabolism of AA by
COX enzymes (COX-1 or COX-2) leads to the synthe-
sis of the 2-series of prostaglandins. Prostaglandin
overproduction has various proinflammatory effects.
Some evidence indicates that MUFAs acids are
associated with the presence of colorectal adenomas.
Pickens et al. (36) showed that palmitoleic acid from
plasma phospholipids fraction was significantly higher
in individuals with adenomas compared to those with
no polyps whereas the percentage of phospholipids
oleic acid did not differ between these groups of
patients. We obtained similar results. 
Since lipid metabolism and the plasma profile of
phospholipids fatty acids are altered in patients with
colorectal cancer, it is suggested that levels of phos -
pholipids FAs may be useful as one of the reliable bio-
markers of this disease (36). Other authors (37) anti-
cipated that analysis of serum metabolite patterns,
including MUFAs and PUFAs, may become a standard
clinical procedure for effective diagnosing and moni-
toring of patients sufferring from colorectal cancer.
Taking into account the dietary heterogeneity in
the population and more or less constant dietary
habits in each individual person, it is not surprising
that the index of individuality (the ratio of intra-indivi-
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dual to inter-individual variation) is very low for each
fatty acid, regardless of lipid’s fraction. Any assump-
tion on the population reference range for total or
individual fatty acids of any origin is impossible.
Proper interpretation of any research requires, among
others, reference values from an optimally selected
control group. In the case of fatty acids of any origin,
proper selection of the control group is practically an
unsolved problem due to the availability of different
diets and high variety of the amount of food consu-
med by each single person. Evidence for this is the
published information on the n-6 PUFAs/n-3 PUFAs
ratio which give the number from 2.6:1 to 5.29:1
(38–40). One of the main reasons of such discrepan-
cy is the increase in the consumption of n-6 fatty
acids and a marked reduction in the consumption of
n-3 fatty acids. In our control group, the lowest value
of n-6 PUFAs/n-3 PUFAs ratio was 1.96:1 and the
highest value was 6.8:1 with the mean value 3.8:1.
The question which should be asked is which value of
the calculated ratio should be taken when the results
in cancer patients are evaluated: the mean value or
median value obtained in a control group selected
according to research criteria or should we take into
account the specific value of the ratio e.g. 2:1? No
simple answer for such a simple question can be
found in the literature.
The present study has certain limitations and
shortcomings. First, the present study is only an expe-
rimental observation and no conclusion can be drawn
regarding the patients survival. Nevertheless, lower
EPA and AA in cancer patients than in controls have
been confirmed. Taking into account the studies
documenting worse outcomes of patients with proxi-
mal colon cancer (23), it might be speculated that the
metabolism of EPA and AA in colorectal cancer
patients is different. Second, our study group was
relatively small and a large-scale prospective study is
required to confirm our results.
In conclusion, in any research concerning the
role of individual fatty acids in colorectal cancer risk
and/or prevention, tumour localization should be
taken into account as a dependent variable.
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